Tuberc Respir Dis > Volume 60(6); 2006 > Article
Tuberculosis and Respiratory Diseases 2006;60(6):625-630.
DOI: https://doi.org/10.4046/trd.2006.60.6.625    Published online June 1, 2006.
Alteration of Coagulation and Fibrinolysis System According to Right Ventricular Dysfunction in Chronic Obstructive Pulmonary Disease.
Young Kim, Yoon Soo Chang, Hyung Jung Kim, Se Kyu Kim, Joon Chang, Chul Min Ahn, Sung Kyu Kim, Jin Young Kwak, Jin Hwa Choi
1Department of Internal Medicine, Yonsei University College of Medicine, Seoul, Korea. khj@yumc.yonsei.ac.kr
2Department of Internal Medicine, Presbyterian Medical Center, Jeonju, Korea.
Abstract
BACKGROUND
Pulmonary hypertension in COPD patients is the result of a direct effect of tobacco smoke on the intrapulmonary vessels with the abnormal production of the mediators that control vasoconstriction, vasodilatation, and vascular cell proliferation, which ultimately lead to aberrant vascular remodeling and physiology. COPD patients are prone to the developmint of an acute and chronic thromboembolism with an elevation of the plasma procoagulant and fibrinolytic markers However, the roles of the coagulation and fibrinolysis system on the right ventricular dysfunction in COPD patients are not well defined. We examined the alteration of the coagulation and fibrinolysis system in COPD patients according to the right ventricular function measured using cardiac multidetector computed tomography (MDCT). METHODS: The right ventricular ejection fraction (RVEF) was measured using cardiac MDCT in 26 patients who were diagnosed with COPD according to the definition of the GOLD guideline. The plasma level of thrombin antithrombin (TAT) and plasminogen activator inhibitor (PAI)-1 were measured using an enzyme linked immunoassay. RESULTS: The plasma TAT was markedly elevated in COPD patients (10.5+/-19.8microgram/L) compared with those of the control (3.4+/-2.5 microgram/L) (p<0.01). However, the plasma PAI-1 in COPD patients (29.6+/-20.7 ng/mL) was similar to that in the controls. The plasma TAT showed a significant inverse relationship with the RVEF measured by the cardiac MDCT in COPD patients (r=-0.645, p<0.01). However, the plasma PAI-1 did not show a relationship with the RVEF (r=0.022, p=0.92). CONCLUSION: These results suggest that the coagulation system in COPD patients is markedly activated, and that the plasma level of TAT might be a marker of a right ventricular dysfunction in COPD patients.
Key Words: Chronic obstructive pulmonary disease, Pulmonary hypertension, Right ventricular failure, Thrombin antithrombin, Plasminogen activator inhibitor-1


ABOUT
ARTICLE & TOPICS
Article category

Browse all articles >

Topics

Browse all articles >

BROWSE ARTICLES
FOR CONTRIBUTORS
Editorial Office
101-605, 58, Banpo-daero, Seocho-gu (Seocho-dong, Seocho Art-Xi), Seoul 06652, Korea
Tel: +82-2-575-3825, +82-2-576-5347    Fax: +82-2-572-6683    E-mail: katrdsubmit@lungkorea.org                

Copyright © 2024 by The Korean Academy of Tuberculosis and Respiratory Diseases. All rights reserved.

Developed in M2PI

Close layer
prev next